China
Africa
Explore chapters and articles related to this topic
No organ can make the body sick
Published in Dinesh Kumar Jain, Homeopathy, 2022
Kent also said, “One organ cannot make another organ sick”. But the whole medical knowledge says that one damaged organ always damages the other organ. I am giving a few examples. Chronic obstructive lung disease is a disease of the lung. After sometime, this disease damages the heart, which is labeled as cor pulmonale. Cancer of one organ affects various organs of the body by metastasis. “Carcinoma in the kidney affects adrenal gland, bone, brain, heart, lung, liver, lymph node, ovary, pancreas, skin, spleen, thyroid gland and muscles” (Lee, 1976, p. 538). Similarly, cancer of many organs can affect other organs of the body. Disease of the pancreas gives rise to diabetes mellitus. Diabetes of prolonged duration damages the kidney, eye, and nervous system. Damage in the brain also causes damage to other organs of the body. Brain controls all functions of the body. Damage in the brain leads to hemiplegia, paraplegia, vision loss, speech loss, etc. Hemiplegia means paralysis of half of the body, and paraplegia means paralysis of both the lower limbs. Conclusively, Kent was again wrong in his observations.
Asthma and COPD
Published in Pudupakkam K Vedanthan, Harold S Nelson, Shripad N Agashe, PA Mahesh, Rohit Katial, Textbook of Allergy for the Clinician, 2021
Balamugesh Thangakunam, Devasahayam J Christopher
According to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases (COPDGold 2019). The course is punctuated by periods of acute symptomatic worsening termed as exacerbations. It is usually associated with significant concomitant chronic diseases which increase its morbidity and mortality (COPDGold 2019). Globally, mortality due to COPD is increasing and at present it has become the fourth leading cause of death (GINAsthma 2011).
Pulmonary rehabilitation and primary care
Published in Claudio F. Donner, Nicolino Ambrosino, Roger S. Goldstein, Pulmonary Rehabilitation, 2020
The World Health Organization has stated that societies are unprepared to manage the burden of aging and chronic illnesses (1). Chronic obstructive lung disease (COPD) is increasingly becoming part of the landscape of chronic disease, and the ubiquitous presence of comorbidities further confounds management strategies. Patients are calling for individualized care and a specific focus on medical treatments, while clinicians are increasingly required to be productive as documented by the volume of patient visits. It has been said that 80% of patients with COPD get their care from the PC clinicians, and frequently these patients do not have access to a pulmonologist (2). It is also well known that diagnosis of COPD is frequently missed due to the underperformance of pulmonary function testing, and many patients are not diagnosed despite having the illness (3). It should not be surprising, then, that patients with COPD, along with other chronic lung diseases, will continue to end up in clinicians’ offices and emergency facilities, not having received optimal preventive care. Paradigm changes are needed to promote better access to disease-specific expertise.
Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview
Published in Expert Review of Clinical Pharmacology, 2022
Maria Gabriella Matera, Barbara Rinaldi, Carmela Belardo, Mario Cazzola
In patients with COPD with persistent but not severe symptoms, those with severe symptoms but no frequent or severe exacerbations, and those with frequent nonsymptomatic exacerbations, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy recommends monotherapy with long-acting bronchodilators [2]. However, LAMA+LABA is recommended as first-line therapy in the most symptomatic subjects, those with a COPD Assessment Test (CAT) ≥20. In the event of no or insufficient clinical response to monotherapy, after verification of compliance and correct inhalation technique, escalation of therapy to LAMA+LABA is planned. If the goal is to reduce dyspnea, LAMA+LABA is the recommended therapy. Such treatment is also recommended if the goal is to reduce exacerbations in patients with <300 eosinophils·μL−1 in the blood or at low risk of exacerbation (those with a maximum of 1 exacerbation in the previous year without requiring hospital care) and no history of asthma.
Resistance training using different elastic components offers similar gains on muscle strength to weight machine equipment in Individuals with COPD: A randomized controlled trial
Published in Physiotherapy Theory and Practice, 2022
Ana Paula Coelho Figueira Freire, Carlos Augusto Marçal Camillo, Bruna Spolador de Alencar Silva, Juliana Souza Uzeloto, Fabiano Francisco de Lima, Luis Alberto Gobbo, Dionei Ramos, Ercy Mara Cipulo Ramos
Participants were included if they had a primary diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD I to IV) (Vogelmeier et al., 2017); presented with clinical stability (i.e. without exacerbations or changes in medications for at least 30 days); did not smoke in the last year; and did not present any condition or disease limiting exercise performance. Participants were recruited from medical clinics and the study was advertised on social media and local television. Participants were excluded from the analyses if they withdrew consent or suffered from an exacerbation episode during the period of the study. Participants were informed about research aims and procedures and, upon acceptance, provided an informed consent form. The present study was approved by the institutional review board (CAAE: 46065315.7.0000.5402). The trial was registered in the Brazilian Clinical Trials Registry (#RBR-6V9SJJ).
Outcomes and Contemporary Trends in Surgical vs Transcatheter Aortic Valve Replacement in Patients with Chronic Obstructive Pulmonary Disease
Published in Structural Heart, 2021
Muhammad Zia Khan, Anas A. Alharbi, Salman Zahid, Muhammad U. Khan, Waqas Ullah, Yasar Sattar, Muhammad Rashid, Asim Kichloo, Muhammad Bilal Munir, Sudarshan Balla
Chronic obstructive lung disease (COPD) is one of the leading causes of death in the United States as it affects around 5% of the general population.1,2 Aortic valve replacement (AVR) has been shown to improve the quality of life and New York Heart Association functional status in patients with COPD.3,4 COPD is also a common morbidity, with a prevalence of around 20% among those undergoing surgical aortic valve replacement (SAVR) and between 12.5% and 43.4% among those undergoing transcatheter aortic valve replacement (TAVR).5–12 COPD as a risk factor is associated with worse outcomes in patients undergoing either TAVR or SAVR and is one of the main reasons for patients to be denied for SAVR.3,4,13 There is a paucity of data on contemporary trends of both procedures since the approval of the TAVR procedure in the COPD population, especially since recent approval in intermediate-risk groups and with the recent generation of TAVR devices which have lower complications.14–17 The objective of the present study is to compare contemporary trends of COPD patients who underwent AVR and assess in-hospital outcomes between patients who underwent TAVR and SAVR procedures using the nationally representative database of National Inpatient Sample (NIS).